NASDAQ:PETX - Aratana Therapeutics Stock Price, News, & Analysis

$4.89
+0.15 (+3.16 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
$4.73
Now: $4.89
$4.90
50-Day Range
$4.63
MA: $4.79
$4.94
52-Week Range
$3.30
Now: $4.89
$7.16
Volume396,400 shs
Average Volume822,194 shs
Market Capitalization$239.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.41 million
Book Value$2.07 per share

Profitability

Net Income$-14,720,000.00

Miscellaneous

Employees83
Market Cap$239.46 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $7.36 million during the quarter, compared to the consensus estimate of $6.98 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. View Aratana Therapeutics' Earnings History.

When is Aratana Therapeutics' next earnings date?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Aratana Therapeutics.

What price target have analysts set for PETX?

4 brokers have issued 12 month target prices for Aratana Therapeutics' stock. Their forecasts range from $4.14 to $5.00. On average, they expect Aratana Therapeutics' share price to reach $4.7250 in the next year. This suggests that the stock has a possible downside of 3.4%. View Analyst Price Targets for Aratana Therapeutics.

What is the consensus analysts' recommendation for Aratana Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.

Has Aratana Therapeutics been receiving favorable news coverage?

Headlines about PETX stock have trended positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Aratana Therapeutics.

Who are some of Aratana Therapeutics' key competitors?

What other stocks do shareholders of Aratana Therapeutics own?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
  • Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
  • Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
  • Mr. Brent A. Standridge, Consultant (Age 61)
  • Ms. Rachel Reiff, Head of Corp. Communications

Who are Aratana Therapeutics' major shareholders?

Aratana Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include General American Investors Co. Inc. (2.89%), Acadian Asset Management LLC (0.90%), Assenagon Asset Management S.A. (0.40%), NJ State Employees Deferred Compensation Plan (0.14%), Bank of Montreal Can (0.09%) and State Board of Administration of Florida Retirement System (0.08%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Which institutional investors are selling Aratana Therapeutics stock?

PETX stock was sold by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., State Board of Administration of Florida Retirement System, Assenagon Asset Management S.A., Menta Capital LLC and Bank of Montreal Can. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Which institutional investors are buying Aratana Therapeutics stock?

PETX stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, NJ State Employees Deferred Compensation Plan, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Hunter Associates Investment Management LLC, Atlas Capital Advisors LLC, Adams Asset Advisors LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $4.89.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $239.46 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.

What is Aratana Therapeutics' official website?

The official website for Aratana Therapeutics is http://www.aratana.com/.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel